Extracellular vesicles as potential biomarkers for diagnosis and recurrence detection of hepatocellular carcinoma.
Extracellular vesicles
Hepatocellular carcinoma
Non-malignant liver disease
Recurrence
Surgery
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
04 Mar 2024
04 Mar 2024
Historique:
received:
16
05
2023
accepted:
28
02
2024
medline:
5
3
2024
pubmed:
5
3
2024
entrez:
4
3
2024
Statut:
epublish
Résumé
Hepatocellular carcinoma (HCC) is the most common primary malignant liver tumor and a leading cause of cancer-related deaths worldwide. However, current diagnostic tools are often invasive and technically limited. In the last decade, non-invasive liquid biopsies have transformed the field of clinical oncology, showcasing the potential of various liquid-biopsy derived analytes, including extracellular vesicles (EVs), to diagnose and monitor HCC progression and metastatic spreading, serving as promising novel biomarkers. A prospective single-center cohort study including 37 HCC patients and 20 patients with non-malignant liver disease (NMLD), as a control group, was conducted. Serum EVs of both groups were analyzed before and after liver surgery. The study utilized microbead-based magnetic particle sorting and flow cytometry to detect 37 characteristic surface proteins of EVs. Furthermore, HCC patients who experienced tumor recurrence (R-HCC) within 12 months after surgery were compared to HCC patients without recurrence (NR-HCC). EVs of R-HCC patients (n = 12/20) showed significantly lower levels of CD31 compared to EVs of NR-HCC patients (p = 0.0033). EVs of NMLD-group showed significantly higher expressions of CD41b than EVs of HCC group (p = 0.0286). The study determined significant short-term changes in CD19 dynamics in EVs of the NMLD-group, with preoperative values being significantly higher than postoperative values (p = 0.0065). This finding of our pilot study suggests EVs could play a role as potential targets for the development of diagnostic and therapeutic approaches for the early and non-invasive detection of HCC recurrence. Further, more in-depth analysis of the specific EV markers are needed to corroborate their potential role as diagnostic and therapeutic targets for HCC.
Identifiants
pubmed: 38438456
doi: 10.1038/s41598-024-55888-8
pii: 10.1038/s41598-024-55888-8
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
5322Informations de copyright
© 2024. The Author(s).
Références
Villanueva, A. Hepatocellular carcinoma. N. Engl. J. Med. 380(15), 1450–1462 (2019).
doi: 10.1056/NEJMra1713263
Tabrizian, P., Jibara, G., Shrager, B., Schwartz, M. & Roayaie, S. Recurrence of hepatocellular cancer after resection: Patterns, treatments, and prognosis. Ann. Surg. 261(5), 947–955 (2015).
doi: 10.1097/SLA.0000000000000710
Llovet, J. M. et al. Immunotherapies for hepatocellular carcinoma. Nat. Rev. Clin. Oncol. 13, 151–172 (2022).
doi: 10.1038/s41571-021-00573-2
Kobayashi, T. et al. Patients with early recurrence of hepatocellular carcinoma have poor prognosis. Hepatobiliary Pancreat. Dis. Int. 16(3), 279–288 (2017).
doi: 10.1016/S1499-3872(16)60181-9
D’Agnano, I. & Berardi, A. C. Extracellular vesicles, a possible theranostic platform strategy for hepatocellular carcinoma-an overview. Cancers (Basel) 12(2), 261 (2020).
doi: 10.3390/cancers12020261
Lone, S. N. et al. Liquid biopsy: A step closer to transform diagnosis, prognosis and future of cancer treatments. Mol. Cancer 21(1), 79 (2022).
doi: 10.1186/s12943-022-01543-7
Sun, N. et al. Purification of HCC-specific extracellular vesicles on nanosubstrates for early HCC detection by digital scoring. Nat. Commun. 11(1), 4489 (2020).
doi: 10.1038/s41467-020-18311-0
van Niel, G., D’Angelo, G. & Raposo, G. Shedding light on the cell biology of extracellular vesicles. Nat. Rev. Mol. Cell Biol. 19(4), 213–228 (2018).
doi: 10.1038/nrm.2017.125
Liu, J. et al. Extracellular vesicles in liquid biopsies: Potential for disease diagnosis. Biomed. Res. Int. 2021, 6611244 (2021).
Han, Q., Zhao, H., Jiang, Y., Yin, C. & Zhang, J. HCC-derived exosomes: Critical player and target for cancer immune escape. Cells 8(6), 558 (2019).
doi: 10.3390/cells8060558
Hirsova, P. et al. Extracellular vesicles in liver pathobiology: Small particles with big impact. Hepatology 64(6), 2219–2233 (2016).
doi: 10.1002/hep.28814
Lapitz, A., Azkargorta, M., Milkiewicz, P., Olaizola, P., Zhuravleva, E., Grimsrud MM, et al. Liquid biopsy-based protein biomarkers for risk prediction, early diagnosis and prognostication of cholangiocarcinoma. J. Hepatol. (2023).
Hong, Y. M. et al. Risk factors of early recurrence after curative hepatectomy in hepatocellular carcinoma. Tumour. Biol. 39(10), 1010428317720863 (2017).
doi: 10.1177/1010428317720863
Jung, S.-M. et al. Characteristics of early recurrence after curative liver resection for solitary hepatocellular carcinoma. J. Gastrointest. Surg. 23(2), 304–311 (2019).
doi: 10.1007/s11605-018-3927-2
Chan, A. W. H. et al. Development of pre and post-operative models to predict early recurrence of hepatocellular carcinoma after surgical resection. J. Hepatol. 69(6), 1284–1293 (2018).
doi: 10.1016/j.jhep.2018.08.027
Roy, D., Pascher, A., Juratli, M. A. & Sporn, J. C. The potential of aptamer-mediated liquid biopsy for early detection of cancer. Int. J. Mol. Sci. 22(11), 5601 (2021).
doi: 10.3390/ijms22115601
Vogl, T. J. et al. Early dynamic changes in circulating tumor cells and prognostic relevance following interventional radiological treatments in patients with hepatocellular carcinoma. PLoS One. 16(2), e0246527 (2021).
doi: 10.1371/journal.pone.0246527
Juratli, M. A., Struecker, B., Katou, S., Morguel, M. H. & Pascher, A. Einfluss der Molekularpathologie auf die onkologische Chirurgie von Leber- und Gallengangstumoren. Chirurg. 92(11), 1003–1010 (2021).
doi: 10.1007/s00104-021-01495-6
Thietart, S. & Rautou, P.-E. Extracellular vesicles as biomarkers in liver diseases: A clinician’s point of view. J. Hepatol. 73(6), 1507–1525 (2020).
doi: 10.1016/j.jhep.2020.07.014
Julich-Haertel, H. et al. Cancer-associated circulating large extracellular vesicles in cholangiocarcinoma and hepatocellular carcinoma. J. Hepatol. 67(2), 282–292 (2017).
doi: 10.1016/j.jhep.2017.02.024
Wang, J. et al. Extracellular vesicles and hepatocellular carcinoma: Opportunities and challenges. Front. Oncol. 12, 884369 (2022).
doi: 10.3389/fonc.2022.884369
Chen, L. et al. HCC-derived exosomes elicit HCC progression and recurrence by epithelial-mesenchymal transition through MAPK/ERK signalling pathway. Cell Death Dis. 9(5), 513 (2018).
doi: 10.1038/s41419-018-0534-9
Couri, T. & Pillai, A. Goals and targets for personalized therapy for HCC. Hepatol. Int. 13(2), 125–137 (2019).
doi: 10.1007/s12072-018-9919-1
Li, X. et al. CD19, from bench to bedside. Immunol. Lett. 183, 86–95 (2017).
doi: 10.1016/j.imlet.2017.01.010
Sotillo, E. et al. Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. Cancer Discov. 5(12), 1282–1295 (2015).
doi: 10.1158/2159-8290.CD-15-1020
Li, H. et al. Decreased granzyme B(+)CD19(+)B cells are associated with tumor progression following liver transplantation. Am. J. Cancer Res. 11(9), 4485–4499 (2021).
Qian, H., Yang, L., Zhao, W., Chen, H. & He, S. A comparison of CD105 and CD31 expression in tumor vessels of hepatocellular carcinoma by tissue microarray and flow cytometry. Exp. Ther. Med. 16(4), 2881–2888 (2018).
Zhang, Y.-Y. et al. CD31 regulates metastasis by inducing epithelial-mesenchymal transition in hepatocellular carcinoma via the ITGB1-FAK-Akt signaling pathway. Cancer Lett. 429, 29–40 (2018).
doi: 10.1016/j.canlet.2018.05.004
Wang, J., Xu, X., Jia, J., Wu, C. & Ge, R. Epressions of SE-1, CD31 and CD105 in the vascular endothelial cells and serum of rat with hepatocellular carcinoma. Chin. Med. J. 17 (2010)
Bösmüller, H. et al. Microvessel density and angiogenesis in primary hepatic malignancies: Differential expression of CD31 and VEGFR-2 in hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Pathol. Res. Pract. 214(8), 1136–1141 (2018).
doi: 10.1016/j.prp.2018.06.011